Vemurafenib Seeks Wider Audience

Vemurafenib (Zelboraf ^®; Genentech/Daiichi Sankyo) is a BRAF V600E kinase inhibitor approved for metastatic melanoma.  Since its approval last year, vemurafenib has become the drug of choice for these patients.  BRAF V600E mutant gene is also found in several other solid cancer, including colon, ovarian and thyroid, and certain leukemias.  Zelboraf is making inroads in these cancer types.